Strata Skin Sciences (SSKN) Projected to Post Earnings on Wednesday

Strata Skin Sciences (NASDAQ:SSKN) is expected to be posting its Q1 2026 results after the market closes on Wednesday, August 19th. Analysts expect Strata Skin Sciences to post earnings of ($0.43) per share and revenue of $5.53 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 5:00 PM ET.

Strata Skin Sciences Stock Performance

NASDAQ SSKN opened at $0.00 on Tuesday. The firm has a 50 day simple moving average of $0.06 and a 200-day simple moving average of $0.24. The company has a debt-to-equity ratio of 10.22, a quick ratio of 0.75 and a current ratio of 0.95. Strata Skin Sciences has a one year low of $0.00 and a one year high of $3.86. The firm has a market cap of $588.80, a price-to-earnings ratio of -0.00 and a beta of 0.04.

Institutional Investors Weigh In On Strata Skin Sciences

An institutional investor recently bought a new stake in Strata Skin Sciences stock. Susquehanna International Group LLP purchased a new stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned 0.24% of Strata Skin Sciences as of its most recent SEC filing. 32.43% of the stock is owned by institutional investors and hedge funds.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA?cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.